The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
Join G1 Therapeutics, Inc., a company focused on next-generation cancer therapies, as they review the current management of chemotherapy-induced myelosuppression (CIM). This presentation will highlight a new therapeutic approach to proactively help protect hematopoietic stem and progenitor cells in the bone marrow from chemotherapy-induced damage. Led by Tajuana Bradley, the session will outline the burden and current treatment landscape of CIM and present important information about a novel treatment. Mechanism of action, safety and efficacy data, and dosing and administration information will be discussed.
